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Available online 11 March 2016The angiotensin II type I receptor (AGTR1) has been implicated in diverse aspects of human disease, from the
regulation of blood pressure and cardiovascular homeostasis to cancer progression. We sought to investigate
the role of AGTR1 in cell proliferation, epithelial–mesenchymal transition (EMT), migration, invasion, angiogen-
esis and tumor growth in the breast cancer cell line MCF7. Stable overexpression of AGTR1 was associated with
accelerated cell proliferation, concomitant with increased expression of survival factors including poly(ADP-ri-
bose) polymerase (PARP) and X-linked inhibitor of apoptosis (XIAP), as well as extracellular signal-regulated
kinase (ERK) activation. AGTR1-overexpressing MCF7 cells were more aggressive than their parent line, with
signiﬁcantly increased activity inmigration and invasion assays. These observations were associatedwith chang-
es in EMT markers, including reduced E-cadherin expression and increased p-Smad3, Smad4 and Snail levels.
Treatment with the AGTR1 antagonist losartan attenuated these effects. AGTR1 overexpression also accelerated
tumor growth and increased Ki-67 expression in a xenograft model. This was associated with increased tumor
angiogenesis, as evidenced by a signiﬁcant increase in microvessels in the intratumoral and peritumoral areas,
and enhanced tumor invasion, with the latter response associated with increased EMT marker expression and
matrix metallopeptidase 9 (MMP-9) upregulation. In vivo administration of losartan signiﬁcantly reduced both
tumor growth and angiogenesis. Ourﬁndings suggest that AGTR1plays a signiﬁcant role in tumor aggressiveness,
and its inhibition may have therapeutic implications.
© 2016 Elsevier B.V. All rights reserved.Keywords:
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Angiogenesis1. Introduction
Despite advances in clinical management and a growing under-
standing of tumor biology, breast cancer remains the most frequently
diagnosed cancer and the second leading cause of cancer death among
women worldwide [1]. Breast cancer growth is frequently governed
by activation of the phosphoinositide 3-kinase (PI3K)/Akt pathway, am-
pliﬁcation of human epidermal growth factor receptor (HER) family
members (such as HER2/ErbB2 and EGFR), and the inactivation of
tumor suppressor genes (such as p53, phosphatase and tensin homolog
(PTEN) and breast cancer gene (BRCA)) [2–4].
A recent study has reported pathogenic overexpression of the angio-
tensin II type 1 receptor (AGTR1) in breast cancers [5]. The angiotensin
II receptor family members include AGTR1 and AGTR2, and belong topital Campus, 97 Gurodong-gil,the G-protein-coupled receptor superfamily. These have diverse biolog-
ical functions including the regulation of blood pressure and cardiovas-
cular homeostasis [6,7]. Increasing evidence demonstrates that AGTR1
is involved in cell proliferation via multiple intracellular signaling path-
ways includingmitogen-activated protein kinase (MAPK), PI3K/Akt and
janus kinase/signal transducer and activator of transcription (JAK/
STAT3) in solid malignancies of the pancreas, ovary, prostate and breast
[5,6,8–11]. In addition, a recent clinical study involving DNAmicroarray
analysis revealed that AGTR1 upregulation is associated with approxi-
mately 10–20% of all breast cancer cases that are ER-positive and
HER2-negative. More importantly, AGTR1 is overexpressed more than
20-fold in 15.5% of all breast cancers, with some biopsies showing
more than 100-fold overexpression in primary and metastatic tumors
[5,12]. However, the precise role of AGTR1 overexpression in breast can-
cer tumor progression has not been clearly elucidated.
EMT is an essential step that occurs during both embryonic develop-
ment and cancer progression. The initiation of EMT arises from a loss of
cell polarity and cell–cell adhesion,which enhances the ability of cells to
migrate and invade [13,14]. In breast cancers, EMT can be induced by
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TGF-β, Wnt, Notch and receptor tyrosine kinases (RTKs) [15,16]. Over
the past several decades, the majority of EMT studies have focused on
the TGF-β/Smad signaling pathway [17–19]. The Snail and Smad3/4
transcriptional repressor complex promotes EMT by repressing the
junction component E-cadherin [20]. Decreased E-cadherin has been
associated with tumor invasiveness and advanced tumor stages, as
well as metastasis, leading to poorer clinical outcomes in gastric,
colon, lung, prostate and breast cancers [21–28]. Several previous stud-
ies have reported that Ang II-AGTR1 regulates TGF-β-mediated EMT in
cardiac ﬁbrosis, vascular ﬁbrosis and solid cancers [29–36].
Angiogenesis leads to the formation of new blood vessels and plays
an important role in tumor progression [37,38]. AGTR1 is thought to
play a major role in tumor angiogenesis in ovary, bladder, lung, and
breast cancers [39–41]. Accumulating evidence suggests that the inhibi-
tion of AGTR1 by antagonists such as losartan and candesartan can
suppress angiogenesis, thereby contributing to the suppression of
tumor growth and metastasis [35,42–44]. In the present study, we
sought todeﬁne the oncogenic role of AGTR1 in cell proliferation,migra-
tion, invasion and angiogenesis in breast cancer in vitro and in vivo. We
hypothesize that AGTR1 overexpression promotes cell proliferation and
EMT, thereby accelerating tumor cell growth and angiogenesis in breast
cancer.
2. Materials and methods
2.1. Reagents and antibodies
Triton X-100, propidium iodide (PI), phosphate buffered saline
(PBS) tablets, dimethyl sulfoxide (DMSO), losartan potassium and
angiotensin II were obtained from Sigma-Aldrich (St. Louis, MO, USA).
Phosphatase inhibitor and protease inhibitor cocktail tablets were pur-
chased from Roche Applied Sciences (Penzberg, Germany). The follow-
ing primary antibodieswere used: AGTR1 (Thermo Fisher Scientiﬁc Inc.,
Rockford, IL, USA); total-ERK1/2, phospho-ERK1/2 (Thr202/Tyr204),
phospho-Smad3 (Ser423/425), PARP, and MMP-9 (Cell Signaling,
Beverly, CA, USA); XIAP, Snail, Ki-67, and CD31 (Abcam, Cambridge,
MA, USA); Smad4 and Smad3 (Santa Cruz Biotechnology Inc., CA,
USA); E-cadherin and N-cadherin (BD Biosciences, Franklin Lakes, NJ);
vimentin (Dako, Glostrup, Denmark); and β-actin (Sigma-Aldrich, St
Louis, MO, USA). The secondary antibodies used included horseradish
peroxidase (HRP)-conjugated anti-rabbit and mouse IgG (Bio-Rad
Laboratories, Hercules, CA, USA); Alexa Fluor-488 or -594 goat anti-
mouse and rabbit IgG, and Texas Red-X Phalloidin (Invitrogen, Carlsbad,
CA, USA).
2.2. Cell culture
The human breast cancer cell line MCF7 (American Type Culture
Collection, Manassas, VA, USA) was cultured in RPMI 1640 containing
10% fetal bovine serum (FBS), streptomycin–penicillin (100 U/ml) and
Fungizone (0.625 μg/ml). Cells were incubated at 37 °C in an atmo-
sphere of 5% CO2.
2.3. Stabilized AGTR1 overexpression in MCF7 cells
AGTR1-overexpressing MCF7 cells were generated using a lentiviral
system. The AGTR1 gene was ampliﬁed by PCR using speciﬁc primers
(enzyme site: NheI/NotI), and then inserted into a dual promoter
lentivector (CD550A-1, System Biosciences, USA). Viruses were
produced with lentiviral packaging, and transfected into HEK293T
producer cells. Pseudoviral particles were collected and concentrated
via centrifugation, and then transfected into MCF7 target cells. After
the infection, puromycin selection was performed, and single colonies
were isolated from a dish. The ﬁnal concentration of puromycin was
3 μg/ml, and no mycoplasmas were detected in the resultant cell lines.2.4. Si-RNA for Smad4 transfection
Cells were seeded into 6-well plates 24 h prior to transfection. The
AGTR1-overexpressing MCF7 cells were transfected with si-Smad4
(Invitrogen, Carlsbad, USA) or control si-RNA (0–200 nM) using Lipo-
fectamine 2000 (Invitrogen, Carlsbad, CA) for 48 h according to the
manufacturer's instructions. The Smad4 Si-RNA sequences were as
follows: 5′-GGA GAG ACG UUU AAG GUC CCU UCA A-3′ and 5′-UUG
AAG GGA CCU UAA ACG UCU CUC C-3′.
2.5. Cell viability assay
Cell viability was assessed using the CellTiter 96* Aqueous One
Solution Cell Proliferation Assay [MTS, 3-(4,5-dimethylthiazol-2-
yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazoli-
um] (Promega, Madison, WI, USA) according to the manufacturer's
instructions. The quantity of formazan product was determined by
measuring absorbance at 490 nm using a Spectramax Plus 384 mi-
croplate analyzer (Molecular Devices, Sunnyvale, CA, USA).
2.6. Western blot analysis
Cells were solubilized in lysis buffer (30mMNaCl, 0.5% Triton X-100,
50 mM Tris–HCl; pH 7.4) containing a cocktail of phosphatase and pro-
tease inhibitors. Supernatant was collected (14,000 ×g, 4 °C, 20 min)
and protein concentration was determined with a Bradford protein
assay kit (Bio-Rad Laboratories). Equal quantities of protein (30 μg)
were subjected to SDS-PAGE and electrotransferred onto nitrocellulose
membranes (GE Healthcare Life Science, Buckinghamshire, UK). The
membraneswere incubated overnight at 4 °Cwith primary antibodies di-
luted in 5% BSA [AGTR1 (1:1000), t-ERK1/2 (1:2000), p-ERK1/2 (1:2000),
PARP (1:2000), XIAP (1:2000), E-cadherin (1:2000), N-cadherin
(1:2000), p-Smad3 (1:1000), Smad4 (1:2000), Snail (1:2000) and β-
actin (1:5000)], followed by incubation with horseradish peroxidase
(HRP)-conjugated rabbit ormouse IgG (1:3000–1:10,000). Signal intensi-
ty was detected using an Enhanced Chemiluminescence Kit (Thermo
Scientiﬁc Inc., Rockford, IL, USA) and x-ray ﬁlm (Agfa Healthcare,Mortsel,
Belgium) and quantitated using AlphaEaseFC software (Alpha Innotech,
San Leandro, CA, USA).
2.7. RT-PCR analysis
Total RNAwas extracted using an RNeasymini kit (Qiagen, Valencia,
CA, USA), according to themanufacturer's instructions. Ampliﬁcation of
transcripts was achieved by reverse transcriptase-polymerase chain re-
action (RT-PCR) using 1 μg/μl total RNA,MolonyMurine Leukemia Virus
reverse transcriptase (MMLV; Gibco/BRL, Gaithersburg, MD, USA), and
oligo-d(T)15 primers (Roche Applied Sciences). PCR ampliﬁcation was
achieved using a Takara PCR Thermal Cycler (Thermo Scientiﬁc Inc.,
Rockford, IL) with the following primers: AGTR1, forward 5′-GATGAT
TGTCCCAAAGCTGG-3′ and reverse 5′-TAGGTAATTGCCAAAGGGCC-3′
and actin, forward 5′-ACCCAGATGTTTGAGAC-3 and reverse 5′-GGAG
TTGAAGGTAGTTTCGT-3′. The PCR products were separated on 1.2%
agarose gels and visualized using a Gel Doc™ XR+ System (Bio-Rad
Laboratories).
2.8. Immunocytochemistry
Cells on 8-well chamber slides (BD Biosciences, Franklin Lakes, NJ)
were ﬁxedwith 4% paraformaldehyde, washedwith PBS, and incubated
with 0.2% Triton X-100 for 10 min. Primary antibodies in antibody-
diluent (Dako, Glostrup, Denmark) were incubated overnight at 4 °C
and then incubatedwith ﬂuorescence-conjugated secondary antibodies
(Alexa Fluor®-488 or -594). Cells were mounted with ProLong Gold
Antifade Reagent with DAPI (Life Technologies, Carlsbad, CA, USA).
Images were acquired using a Carl Zeiss confocal microscope (Weimar,
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proﬁling, as previously described [45].
2.9. Wound healing assay
Cell monolayers (80% conﬂuence) were scratched with a 200 μl pi-
pette tip, and wound closure was monitored over a 48 h period. Images
were captured at 0 and 48 h afterwoundingusing aNikon Eclipse TE300
microscope (Nikon, Tokyo, Japan).
2.10. Invasion assay
Invasion chambers were coated with matrigel matrix (BD Biosci-
ences, Franklin Lakes, NJ) according to the manufacturer's recommen-
dations. Cells (1.5 × 105) were trypsinized, washed and suspendedFig. 1. AGTR1 overexpression increases cell proliferation and upregulates survival factors. (A) A
AGTR1. Cells were immunostained for AGTR1 (green) and nuclei were counter-stained with D
intensity (green) and subcellular localization (white arrows) were analyzed by confocal micr
overexpression on cell proliferation. Cell proliferation was assessed using MTS assay and da
AGTR1-c1, ***p b 0.001; MCF7 vs AGTR1-c2, ###p b 0.001). (D) Total-ERK1/2 and phospho-ER
-c2 overexpression cell lines as determined by Western blot analysis. Quantiﬁcation of the ph
was used as loading control. (E) Effect of losartan on cell viability. Cells were treated with lo
AGTR1-overexpressing cells (**p b 0.01; DMSO control vs losartan treatment groups). (F)
overexpressing cells. Cells were treated with Ang II (0–10 μM) and/or losartan (10 μM) for 4
(n = 3 independent experiments) and were analyzed by two-way ANOVA followed by Bonfe
alone vs Ang II + losartan treatment).onto the upper chamber with serum-free media. Conditioned media
was added to the lower chambers. The chambers were incubated for
48 h at 37 °C in a humidiﬁed atmosphere of 5% CO2. Invaded cells
were ﬁxed and stainedwith Diff-Quik (Sysmex, Kobe, Japan) and count-
ed under a BX51 microscope (Olympus, Tokyo, Japan).
2.11. Xenograft mouse model
All animal procedures were carried out in accordance with animal
care guidelines approved by the Korea University Institutional Animal
Care and Use Committee (IACUC). Five-week-old female BALB/c nude
mice were obtained from the Shizuoka Laboratory Animal Center
(Shizuoka, Japan) and housed in a speciﬁc pathogen-free environment.
The animals were acclimated for 1 week prior to the study and had free
access to food andwater.MCF7 cells (1× 107) or AGTR1-overexpressingGTR1 mRNA and protein expression normalized to β-actin. (B) Subcellular localization of
API (blue). Selected areas from merged images are shown at high magniﬁcation. AGTR1
oscopy using the intensity proﬁle tool (straight red line with arrow). (C) Effect of AGTR1
ta were analyzed by two-way ANOVA followed by Bonferroni's post-hoc test (MCF7 vs
K1/2, as well as total PARP and XIAP protein expression in MCF7 cells and the AGTR1-c1,
ospho-ERK/ERK ratio and levels of PARP and XIAP are shown in the right panels. β-Actin
sartan (0–50 μM) for 48 h and cell viability was determined by MTS assay in MCF7 and
Inﬂuence of losartan on cell viability in the presence of Ang II in MCF7 and AGTR1-
8 h and cell viability was analyzed by MTS assay. Results are expressed as mean ± SEM
rroni's post-hoc test (**p b 0.01; DMSO control vs Ang II; #p b 0.05, ###p b 0.001, Ang II
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100 μl of matrigel and implanted subcutaneously in the left or right
ﬂank of 6-week-old BALB/c nude female mice (n = 10/each group).
Mice were inoculated with 17β-estradiol pellets (1.72 mg, Innovative
Research of America, USA) 48 h before injection of cells. Tumor volumes
were measured using a caliper and calculated using the formula V =
(Length × Width2) / 2.
2.12. Mammary fat pad xenograft model
5 × 106 AGTR1-overexpressing cells were injected into the fourth
mammary fat pads in six-week-old female BALB/c nude mice. AfterFig. 2. Overexpression of AGTR1 induces EMT in MCF7 cells.(A) Effect of AGTR1 overexpressio
cytoskeletal F-actin in MCF7 and AGTR1-c1 and -c2 cell lines. Cells were stained with ﬂuor
AGTR1 overexpression on levels of EMT-related markers. Quantitative graphs of E-cadherin, N
shown in the right panel. (D–E) Inﬂuence of AGTR1 on p-Smad3/Snail expression and subc
E) and nuclei were stained with DAPI (blue). Immunoﬂuorescence analysis reveals increased
Intensity proﬁles are represented in arbitrary units as deﬁned by the software and scaled on
treated with losartan (10 μM) for 6 days and total-ERK1/2, phospho-ERK1/2, E-cadherin, N-cad9 days, the animals were randomized into 2 groups (n = 5/each
group) and vehicle control (PBS) or losartan potassium (90 mg/kg,
3 times/week) were administered intraperitoneally. Tumor volumes
(V) were measured by caliper (3 times/week) and calculated using
the following formula; V = (Length × Width2) / 2.
2.13. Immunohistochemistry
At sacriﬁce, tumor tissues were removed, ﬁxed in 10% neutral-
buffered formalin, and parafﬁn embedded. Tissue sections of 4-μm
thickness were mounted on positively-charged glass slides and then
deparafﬁnized with xylene and dehydrated through a graded alcoholn on MCF7 cell morphology (×200 magniﬁcation). (B) Differential expression patterns of
escent phalloidin (F-actin, red) and nuclei were stained with DAPI (blue). (C) Effect of
-cadherin, Smad4 and Snail expression, and the ratio of phospho-Smad3/total-Smad3 are
ellular localization. Cells were immunostained for p-Smad3 (green, D) or Snail (green,
nuclear accumulation of p-Smad3 and Snail. Images are shown at ×500 magniﬁcation.
the y-axis. (F) Effect of losartan treatment on AGTR1-induced EMT. AGTR1-c2 cells were
herin, Smad4 and Snail protein levels were determined by Western blot analysis.
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buffer (pH 6.0) for immunoﬂuorescence analysis. Tissue sections with
primary antibodies (Ki-67; 1:200 or CD31; 1:100, E-cadherin; 1:100
and vimentin; 1:200, MMP-9; 1:100) in antibody-diluentwere incubat-
ed overnight at 4 °C. For secondary antibody reactions, the sectionswere
incubated with ﬂuorescent Alexa Fluor® 594 or 488-conjugated
secondary antibody (Invitrogen, Carlsbad, CA, USA) at RT for 2 h, and
then mounted with ProLong gold anti-fade reagent with DAPI. Images
were acquired using a Carl Zeiss confocal microscope and ﬂuorescence
intensity was analyzed using a histogram tool in the Carl Zeiss software
package.
2.14. Statistical analysis
All datawere analyzed using GraphPad Prism 5.0 statistical software
(San Diego, CA, USA). The results are presented as mean ± SEM of at
least three independent experiments. Data were analyzed by Student's
t-test and two-way ANOVA, as appropriate. A two-way ANOVA was
used to assess the effects and interactions of two variables and multiple
comparisons were achieved using Bonferroni's post hoc test. Statistical
signiﬁcance was deﬁned at p b 0.05.
3. Results
3.1. AGTR1 overexpression promotes cell proliferation and upregulates
survival-related factors
To investigate the role of AGTR1 in breast cancer, MCF7 cells were
stably transfected with an expression construct carrying cDNA
for human full-length AGTR1, and named AGTR1 clone number 1
(AGTR1-c1) and clone number 2 (AGTR1-c2). Western blot and RT-
PCR analyses were performed to conﬁrm the stable overexpression of
AGTR1. AGTR1 levels were conﬁrmed to be more than 4- to 5-fold
higher in comparison to the parental MCF7 cells (Fig. 1A). Subcellular
localization of AGTR1 was also conﬁrmed by immunocytochemistryFig. 3. AGTR1 accelerates cell migration and invasion. (A) Cell migration was assessed over 48
magniﬁcation). Graph values represent the average relative migratory distance (right panel,
with an inverted microscope (×200 magniﬁcation). The total number of invading cells in the ﬁusing confocal microscopy. Distribution of AGTR1 was localized to the
plasma membrane, with green ﬂuorescent intensity markedly higher
in the AGTR1-c1 and -c2 cells (Fig. 1B).
MTS assays revealed that AGTR1-c1 and -c2 cells proliferated signif-
icantly faster than their parental MCF7 cells (###p b 0.001, ***p b 0.001,
Fig. 1C). This response was associated with the increased expression of
survival factors such as PARP and XIAP as well as ERK activation
(Fig. 1D).
To explore the effect of losartan on cell viability, cells were treated
with various concentrations of losartan (0–50 μM) for 48 h. A signiﬁcant
effect on cell viability was observed at 50 μM of losartan in AGTR1-c1
and -c2 cells. However, losartan had no signiﬁcant inhibitory effect in
the parental MCF7 cells (Fig. 1E). We next examined the effect of
AGTR1 overexpression on cell viability upon stimulationwith angioten-
sin II (Ang II), a bioactive ligand of AGTR1, and the antagonist losartan
for 48 h. Ang II signiﬁcantly increased cell proliferation in AGTR1-c1
and -c2 cells in a dose-dependent manner (CTL vs Ang II **p b 0.01),
whereas the parental MCF7 cells were not statistically different. Ang
II-induced cell proliferation was suppressed by losartan challenge
(10 μM) in AGTR1-c1 and -c2 cells (Ang II alone vs combination treat-
ment with Ang II + losartan, #p b 0.05, ###p b 0.001, Fig. 1F).
3.2. AGTR1 overexpression induces EMT
Luminal-typeMCF7 cells exhibited typical features of epithelial cells,
whereas the AGTR1 overexpressing AGTR1-c1 and-c2 cells were
observed to exhibit a mesenchymal-like phenotype (Fig. 2A), including
re-arrangement of cytoskeletal F-actin with elongated spindles
(Fig. 2B). We sought to further conﬁrm whether these changes in cell
morphology were indicative of EMT. Western blot analysis revealed
that AGTR1-c1 and-c2 cells exhibited a loss of E-cadherin and a marked
increase in N-cadherin expression, as well as increased EMT-related
transcription factors such as phospho-Smad3, Smad4 and Snail, when
compared with the parental MCF7 cells. There were no differences in
protein expression of total-Smad3 between the MCF7- and AGTR1-h by wound healing assay. Images were captured by phase contrast microscopy (×100
**p b 0.01). (B) Effect of AGTR1 overexpression on cell invasion. Images were captured
elds were counted and are shown in the right panel (***p b 0.001).
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intensity proﬁling revealed that p-Smad3 and Snail expression was
considerably upregulated and accumulated in the nuclei of AGTR1-
overexpressing cells, whereas their distribution was primarily conﬁned
to the cytoplasm in the parental MCF7 cells (Fig. 2D and E). Importantly,
challenge with the AGTR1 antagonist losartan notably downregulated
N-cadherin, Smad4 and Snail expression, while upregulating E-
cadherin. ERK phosphorylation was also decreased in the AGTR1-
overexpressing cells by losartan treatment (Fig. 2F).
3.3. AGTR1 overexpression promotes breast cancer cell migration and
invasion
Cell migration and invasion are two hallmarks of EMT in human
mammary epithelial cells [46]. To investigate the effect of AGTR1
overexpression on cell migration and invasion, wound healing and
matrigel invasion assays were performed. As shown in Fig. 2A, MCF7
cells exhibited a typical epithelial phenotype with an absence of inva-
sive or migratory behavior. In contrast, the AGTR1-overexpressing
cells acquired both migratory (**p b 0.01, Fig. 3A) and invasive proper-
ties (***p b 0.001, Fig. 3B).
3.4. Inhibition of Smad4 reverses AGTR1-induced EMT
To examine whether AGTR1-induced EMT was mediated by Smad
action, knockdown of Smad4, as a major Smad signaling component,
was undertaken. AGTR1-c1 and-c2 cells were transiently transfected
with si-Smad4 or si-CTL for 48 h to reduce Smad4 activity, before cellFig. 4.Knockdown of Smad4 suppresses AGTR1-induced EMT. (A–C) AGTR1-c1 and-c2 cells wer
knockdown on cell morphology in AGTR1-c1 and -c2 cells. (B) Smad4 knockdown upregulate
signal intensities of Smad4 and E-cadherin are shown (bottom panel, *p b 0.05, ***p b 0.00
cytoskeletal F-actin. Cells were immunostained for E-cadherin (green) or F-actin (red) and immorphology was assessed. Phase contrast analysis revealed that RNA
interference-mediated downregulation of Smad4 induced morphologi-
cal changes in the AGTR1-overexpressing cells from a spindle-shaped
mesenchymal phenotype to a cobblestone-shaped epithelial phenotype
(Fig. 4A). To further support this observation, we examined the effect of
Smad4 knockdown on E-cadherin expression in AGTR1-overexpressing
cells. E-cadherin level was completely restored by blockage of Smad4 in
both AGTR1-c1 and -c2 cells (*p b 0.05, ***p b 0.001, Fig. 4B). Immuno-
ﬂuorescence analysis also revealed that si-Smad4-transfected cells
exhibited a predominant epithelial-like phenotype with a marked in-
crease in E-cadherin levels (Fig. 4C). These results suggest that induc-
tion of EMT by AGTR1 is mediated by the Smad signaling pathway.
3.5. AGTR1 promotes tumor growth in vivo
To conﬁrm the physiological relevance of our in vitro observa-
tions, we examined the effects of AGTR1 on tumor growth using
xenografted mice harboring both MCF7 and AGTR1-overexpressing
MCF7 cells. Parental MCF7 and AGTR1-overexpressing MCF7 cells
were subcutaneously injected into the left and right ﬂanks of 6-
week Balb/c nude female mice. Tumor volumes were measured
every other day for three weeks with a caliper. Over the course of
21 days, we observed that the AGTR1 tumors exhibited a signiﬁcant
increase in volume (*p b 0.05, ***p b 0.001, Fig. 5A and B) and weight
(***p b 0.001, Fig. 5C) as well as a marked increase in the number of
Ki-67-positive cells (***p b 0.001, Fig. 5D) compared to the MCF7 tu-
mors. To support our in vitro observations, EMT markers were
assessed by immunohistochemical analysis. AGTR1-overexpressinge transiently transfectedwith si-Smad4 or si-CTL (0–200 nM) for 48 h. (A) Effect of Smad4
s E-cadherin protein levels, as determined by Western blot assay. Quantitative graphs of
1). (C) Inﬂuence of Smad4 knockdown on E-cadherin expression and organization of
ages were captured with a confocal microscope.
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Fig. 5E) and an upregulation of vimentin expression (**p b 0.01,
Fig. 5F). Furthermore, we observed that AGTR1 tumor cells had in-
vaded into the marginal adipose tissue and muscle layer (Fig. 5G).
Matrix metalloproteinase MMP-9 is extensively expressed in
aggressive malignant tumors, and the degradation of extracellular
matrix (ECM) by MMPs contributes toward tumor invasion andFig. 5. Overexpression of AGTR1 increases tumor growth in a mouse xenograft model. (A–D)
insertion of MCF7 cells (left ﬂanks, a) or AGTR1-overexpressing MCF7 cells (right ﬂanks,
statistically signiﬁcant increases in tumor growth (B, *p b 0.05, ***p b 0.001) and tumor weigh
MCF7-AGTR1 tumors. Tumor tissues were immunostained with Ki-67 (red) and nuclei were
tumors when compared to the control groups. The selected areas in merged images are shown
is shown in the bottom panel (***p b 0.001). (E–F) Expression of E-cadherin and vimentin in
red) or vimentin (F, red) with DAPI (**p b 0.01). (G) Representative H&E images from MCF7
muscle layer. Black arrows and blue arrows indicate adipose and muscle tissue invasion, re
sections were immunostained with MMP-9 (red) and nuclei were stained with DAPI (nuclei, bangiogenesis [47,48]. Recent studies have shown that Ang II-
AGTR1 increases MMP-9 expression, which accelerates cell migra-
tion and invasion, whereas knockdown of MMP-9 reduces these
events in breast cancer cells [49,50]. To examine whether AGTR1-
induced invasiveness is associated with MMP-9 expression, immu-
nohistochemical analysis of the xenograft tumor samples for MMP-
9 was performed. A signiﬁcant upregulation of MMP-9 expressionEffect of AGTR1 on tumor growth in vivo. (A) Images of tumors formed by subcutaneous
b) in female 6-week old Balb/c nude mice (n = 10). (B–C) AGTR1 tumors exhibited
t (C, ***p b 0.001) when compared to MCF7 tumors. (D) Expression of Ki-67 in MCF7 and
stained with DAPI (blue). The number of Ki-67-positive cells was higher in the AGTR1
at high magniﬁcation (×1000). Quantitative graph of the number of Ki-67-positive cells
MCF7 and MCF7-AGTR1 tumors. Tissue sections were immunostained for E-cadherin (E,
and MCF7-AGTR1 tumors. AGTR1 tumor cells invaded into both the adipose tissue and
spectively. (H) Expression of MMP-9 in MCF7 and MCF7-AGTR1 tumors. Tumor tissue
lue). Quantitation of MMP-9 signal intensity is shown in the right panel (*p b 0.05).
Fig. 6. AGTR1 enhances tumor angiogenesis in vivo. (A) Images of blood vessels between
MCF7 and MCF7-AGTR1 tumors and surrounding tissue. (B) AGTR1 tumors exhibited a
signiﬁcant increase in microvessel density (MVD). Tumor tissues were immunostained
with a speciﬁc endothelial cell marker CD31 (red) and nuclei were stained with DAPI
(blue). Quantitative graphs represent the number of CD31-positive microvessels in
peritumoral (***p b 0.001) and intratumoral areas (**p b 0.01).
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their control counterparts (*p b 0.05, 5H).
3.6. AGTR1 promotes angiogenesis in vivo
Tumor growth is thought to be in part reliant upon the stimulation of
tumor angiogenesis [51]. To investigate the effect of AGTR1 overexpres-
sion on angiogenesis, blood vessel growthwasobserved after the exper-
imental animals were sacriﬁced. AGTR1 overexpression promoted
angiogenesis, with an increase in the number and size of the blood ves-
sels present between the tumors and the surrounding tissue (Fig. 6A).
Microvessel density (MVD) assays were used for the examination of
tumor angiogenesis with the speciﬁc vascular endothelial cell marker
CD31 [52,53]. The number of CD31-positive microvessels in the
peritumoral and intratumoral areas was signiﬁcantly increased in the
AGTR1-overexpressing tumors when compared to the control tumors
(**p b 0.01, ***p b 0.001, Fig. 6B).
3.7. Losartan inhibits tumor growth and angiogenesis upregulated by
AGTR1 overexpression
Finally, we examined the effect of losartan on tumor growth using a
mammary fat pad xenograft model with the AGTR1-overexpressing
cells. 5 × 106 cells were orthotopically implanted into the mammary
fat pads of Balb/c female nude mice, and after 9 days, control vehicle
(PBS) or losartan (90 mg/kg, body weight) was administered every
other day. Losartan administration resulted in a signiﬁcant reduction
in tumor growth (**p b 0.01, Fig. 7A) and a signiﬁcant decrease in the
number of Ki-67-positive cells in the AGTR1-overexpressing xenograft
tumors (**p b 0.01, Fig. 7B). Losartan administration notably upregulat-
ed E-cadherin (***p b 0.001, Fig. 7C) and suppressed vimentin expres-
sion (**p b 0.01, Fig. 7D). Furthermore, microvessel density analysis
revealed that the number of CD31-positive microvessels in both the
peritumoral and intratumoral areas was signiﬁcantly decreased in the
losartan-treated groups (***p b 0.001, Fig. 7E).
4. Discussion
Our observations suggest that AGTR1 overexpression promotes cell
growth, EMT, cell migration and invasion in vitro, while stimulating
tumor growth in vivo. AGTR1-overexpression resulted in an aggressive
phenotype characterized by increased levels of themesenchymalmark-
er vimentin and enhanced tumor invasiveness, as well as increased
microvessel density. These in vitro and in vivo events were notably at-
tenuated by the inhibition of AGTR1 by losartan.
AGTR1 activation is primarily regulated by its ligand, angiotensin II
(Ang II) as well as antagonists including angiotensin receptor blockers
(ARBs) such as losartan, telmisartan, valsartan and candesartan [54,
55]. In this study, the AGTR1 activation observed in the MCF7 cells ap-
pears to be Ang II-independent. AGTR1 overexpression promoted cell
growth, concomitant with increases in PARP and XIAP protein content,
but in the absence of Ang II stimulation in vitro. Recent studies have
demonstrated that renin–angiotensin system (RAS) components in-
cluding angiotensin I/II, angiotensinogen, renin, and angiotensin
converting enzyme (ACE) are expressed in MCF7, MDA-MB-468 and
T47D human breast cancer cell lines and breast cancer tissue [56,57].
It is therefore possible that interplay between higher levels of AGTR1
and the local Ang II/RAS components activates the AGTR1 signaling
pathway, enhancing breast cancer cell proliferation.
Inhibitor of apoptosis proteins (IAPs) are broad regulators of survival
signaling relevant to malignant neoplasms. In particular, XIAP is the
most commonly overexpressed in breast cancer, and promotes cell sur-
vival, migration and invasion, as well as evasion of apoptosis via the
inactivation of caspases 3, 7 and 9 [58,59]. PARP is essential for DNA
repair and recombination, as well as genomic stability. Its upregulation
helps tumor cells to evade apoptosis, thereby promoting cancerprogression [60]. In this context, we examined whether AGTR1-induced
cell proliferationwas associatedwith XIAP and PARP expression. The con-
siderable upregulation of these factors inAGTR1-c1 and -c2 cells observed
may contribute to an acceleration of breast cancer cell proliferation.
Recent studies have shown that ERK1/2 phosphorylation is mediat-
ed by AGTR1 activation via an Ang II-independent pathway [5,61].
Forced expression of AGTR1 is known to increase ERK phosphorylation,
regardless of Ang II stimulation in human mammary epithelial HME
cells [5]. Moreover, mechanical factors such as stretch and shear stress
induce AGTR1 activation in the absence of Ang II stimulation and subse-
quently increases ERK and P13K activation. These responses can be
blocked by candesartan treatment in cardiomyocytes and Chinese
hamster ovary CHO cells [61]. In agreement with these observations,
we found that AGTR1 overexpression increased the phospho-ERK/
total-ERK ratio, whereas its effect was diminished following losartan
challenge. Exposure to Ang II signiﬁcantly promoted cell proliferation
in AGTR1-overexpressing MCF7 cells, but no statistically signiﬁcant
difference between Ang II and the control groups was observed in the
parental MCF7 cells. Losartan also had a greater inhibitory effect on
Ang II-induced cell viability in the AGTR1-overexpressing MCF7 cells
compared to the parental line.
To examine whether AGTR1 is indeed involved in breast cancer
proliferation, mice were xenografted with both MCF7 and AGTR1-
overexpressingMCF7 cells. Our in vitro observationswere in agreement
with the in vivo observations showing that AGTR1-overexpressing tu-
mors exhibited a markedly higher tumor growth rate and larger
tumor burden, as indicated by the considerable upregulation of Ki-67.
Blockade of AGTR1 signiﬁcantly retarded tumor growth as well as sig-
niﬁcantly reduced the number of Ki-67-positive cells. These ﬁndings
suggest that the targeting of AGTR1 could be a potential anticancer
strategy for the treatment of breast cancer.
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yet to be fully elucidated. AGTR1-overexpressing cells exhibited a
mesenchymal-like phenotype, together with an increase in nuclear
accumulation of phospho-Smad3 and Snail, increased Smad4 and
N-cadherin levels and a loss of E-cadherin. The transcription factor
Smad4 is a major determinant of EMT, and operates via the Smad/
TGF-β pathway [17–19]. Upon TGF-β1 stimulation, the Smad3/4-
Snail complex forms, which can then bind to Smad binding element
(SBE) and the promoter of E-cadherin, resulting in the induction of
EMT due to E-cadherin suppression [20]. Inhibition of Smad4 has
been shown to suppress TGF-β-induced responses associated with
EMT in mammary epithelial NMuMG cells in vitro, and prevents
bone metastasis of MDA-MB-231 cells in vivo [62]. Knockdown of ei-
ther Smad2 or Smad3 also inhibits TGF-β-induced EMT in pulmonary
epithelial cells [63]. Furthermore, recent studies have reported that
AGTR1 stimulation by Ang II induces EMT via the Smad signaling
pathway in renal epithelial cells and vascular smooth muscle cells
in vitro [33,34]. In contrast, AGTR1 antagonism inhibits Smad activa-
tion, which suppresses the induction of EMT [29,30,32]. Our results
showed that knockdown of Smad4 in the AGTR1-overexpressing
cells induced the upregulation of E-cadherin, followed by the induc-
tion of mesenchymal to epithelial transition (MET). LosartanFig. 7. Losartan administration suppresses tumor growth andMVD. (A) Effect of losartan onAGT
fat pads (right and left) of BALB/c nudemice. After 9 days, losartan (90mg/kg, body weight) or
the indicated time durations. Losartan treatment reduced tumor volume (A, **p b 0.01) in AG
sections were immunostained for Ki-67 (1:100, green) with DAPI (blue). The selected areas
percentage of Ki-67-positive cells (**p b 0.01). (C–D) Losartan induced E-cadherin downr
administration signiﬁcantly reduced peritumoral-MVD (***p b 0.001) and intratumoral-MVD (treatment was observed to attenuate these AGTR1-induced re-
sponses by increasing mesenchymal markers and decreasing E-
cadherin levels in vitro and in vivo.
EMT is often associated with aggressive and invasive phenotypes
and malignant tumor progression [64,65]. Clinical evidence demon-
strates that adipose tissue invasion (ATI) of cancer cells at the
tumor margin is a biological indicator of tumor aggressiveness in
early-stage breast cancer, and is correlated with both axillary
lymph node metastasis and a lower survival rate [66]. The AGTR1-
overexpressing cells overall had a more aggressive phenotype and
invaded into the adipose tissue and penetrated the muscle layers at
the tumor margin. This invasiveness was associated with a signiﬁ-
cant upregulation of MMP-9 expression. We found that MMP-9
levels were considerably higher in the AGTR1-overexpressing tu-
mors, an observation in agreement with previous ﬁndings in gastric
and breast cancers [50,67].
Clinical and preclinical data have revealed that intratumoral MVD is
positively correlated with elevated AGTR1 expression in the advanced
stages of ovarian and prostate cancer, resulting in poorer clinical out-
comes [39,40,43,68]. We observed that AGTR1 overexpression in-
creased the number of CD31-positive microvessels in the peritumoral
and intratumoral areas, and this response was strongly suppressed byR1-overexpressing xenograft tumor growth. 5 × 106 cellswere injected into themammary
a vehicle control (PBS) was injected intraperitoneally. Tumor volumes were measured for
TR1-overexpressing xenografts. (B) Effect of losartan on Ki-67 expression. Tumor tissue
in merged images are shown at high magniﬁcation (×1000). The graph represents the
egulation (***p b 0.001) and vimentin upregulation (**p b 0.01) in vivo. (E) Losartan
**p b 0.01).
1080 E. Oh et al. / Biochimica et Biophysica Acta 1863 (2016) 1071–1081losartan administration, suggesting that AGTR1 plays a crucial role in
breast cancer angiogenesis.
In summary, we have observed that AGTR1 overexpression pro-
motes cell proliferation and upregulates the expression of survival
factors in vitro, and that AGTR1-induced EMT appears to be mediated
by the Smad signaling pathway. AGTR1 overexpression also promotes
a more aggressive phenotype with increased cell migration and inva-
sion in vitro and in vivo, and increased tumormicrovessel density indic-
ative of angiogenesis. Our ﬁndings support the notion that AGTR1 is a
potentially useful diagnostic marker and its inhibition may provide an
effective therapeutic strategy for breast cancer treatment.
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